MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics will sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million. The transaction includes the transfer of the manufacturing site, CDMO operations, and associated personnel to Bora, with the deal expected to close in Q3 2026.
Key figures
- Deal Value Usd
- 122500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.